Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis
By LabMedica International staff writers Posted on 19 Apr 2021 |
Image: Mindray Analyzers Help Detect Hematological Parameters to Support COVID-19 Diagnosis and Prognosis (Photo courtesy of Mindray)
Mindray (Shenzhen, China) hematology analyzers are using advanced technologies to detect inflammatory parameters, such as white blood cell count (WBC), neutrophil count, neutrophil-to-lymphocyte ratio (NLR) and red blood cells (RBC) that can support COVID-19 diagnosis and prognosis.
Identifying COVID-19 patients at highest risk for severe disease is important. In order to facilitate early intervention and to manage local hospital resources to mitigate the critical care crises, research is being conducted in routine, low-cost, and suggestive parameters to assist with COVID-19 prognosis and the identification of severe cases. Studies comparing hematological results from good and poor outcome groups of COVID-19 patients have revealed that the best single parameter for predicting the prognosis of severe patients is RDW-SD. Additionally, combined parameters Lym# & RDW-CV as well as Lym# & RDW-SD are better for predicting the prognosis of severe COVID-19. Researchers have also found that HGB is lower in the severe group than in the moderate group. New joint parameters Lym% and HGB have the best sensitivity and specificity. Hence, Lym% and HGB can be used as indicators of disease prognosis.
With advanced technologies, the newly combined hematological parameters, such as Lym% & RDW-SD, Lym# & HGB and NLR & RDW-SD, have been found as supportive predictors during COVID-19 prognostics. More and more covariates can be studied and developed on the Mindray BC-6000 series analyzers. Especially on BC-6800Plus, the RET channel can detect the number, size, and hemoglobin concentration of RBCs and RETs highly sensitive laser scattering technology. Thus, it is recommended to start using self-defined parameters for COVID-19 prognosis now.
Identifying COVID-19 patients at highest risk for severe disease is important. In order to facilitate early intervention and to manage local hospital resources to mitigate the critical care crises, research is being conducted in routine, low-cost, and suggestive parameters to assist with COVID-19 prognosis and the identification of severe cases. Studies comparing hematological results from good and poor outcome groups of COVID-19 patients have revealed that the best single parameter for predicting the prognosis of severe patients is RDW-SD. Additionally, combined parameters Lym# & RDW-CV as well as Lym# & RDW-SD are better for predicting the prognosis of severe COVID-19. Researchers have also found that HGB is lower in the severe group than in the moderate group. New joint parameters Lym% and HGB have the best sensitivity and specificity. Hence, Lym% and HGB can be used as indicators of disease prognosis.
With advanced technologies, the newly combined hematological parameters, such as Lym% & RDW-SD, Lym# & HGB and NLR & RDW-SD, have been found as supportive predictors during COVID-19 prognostics. More and more covariates can be studied and developed on the Mindray BC-6000 series analyzers. Especially on BC-6800Plus, the RET channel can detect the number, size, and hemoglobin concentration of RBCs and RETs highly sensitive laser scattering technology. Thus, it is recommended to start using self-defined parameters for COVID-19 prognosis now.
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants